Plain-English translation of NCT05173714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether combining exercise guidance, strength training, and —a medication approved for weight loss and diabetes—can help people with moderate kidney disease reduce how much time they sit and increase physical activity. The study builds on earlier research showing that sitting less helps protect kidney function, but people struggled to keep up the habit long-term. Researchers want to see if adding strength training and this medication can make the activity program easier to stick with.
People with kidney disease who sit for long periods face faster decline in kidney function and higher risks of diabetes, heart disease, and death. An earlier study showed that reducing sitting time helped, but the benefit didn't last—so researchers are now testing whether adding strength training and the medication can help people maintain these healthier habits over time.
You likely qualify if…
You likely don't qualify if…
If you join, you'll start with 3 months of a 'Sit Less, Interact and Move More' program designed to reduce sitting time. Then you'll continue for 9 more months while receiving guided strength training sessions and taking either the medication or a placebo (sugar pill), depending on which group you're assigned to. Throughout the study, you'll wear a device that tracks your sitting and movement, attend in-person or virtual visits, and work with the research team to build healthier activity habits.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States